Iomai to Initiate Phase II Trial of Influenza Adjuvant Patch
Posted on: Wednesday, 16 April 2008, 09:01 CDT
Iomai has received approval from the Department of Health and Human Services to expand its program to develop an immunostimulant adjuvant patch, for use with an injected H5N1 influenza vaccine.
This decision was based upon positive clinical data generated in a 500-subject, Phase I/II study recently completed by Iomai. Guided by data from this study, Iomai will begin a Phase II dose-ranging study designed to identify the optimum dose of antigen and adjuvant that can be used in a one-dose or two-dose regimen to enhance the immune response to a H5N1 influenza vaccine.
Stanley Erck, president and CEO of Iomai, said: "The Iomai immunostimulant patch has the potential to change how we react to an influenza pandemic, and we will move ahead quickly with the development of this technology. Based on the data from this new Phase II study, Iomai and HHS will evaluate whether to proceed next with a pivotal Phase III trial."
Source: Datamonitor
Related Articles
- QLT Announces Encouraging Phase II Data From Core Study of Punctal Plug Drug Delivery System
- Phase IIb Data Published in the Lancet Show That BG-12, Biogen Idec's Novel Oral Compound, Significantly Reduced Brain Lesions in Patients With Multiple Sclerosis
- Novavax Completes Enrollment in Phase I/IIa Pandemic Influenza Vaccine Clinical Trial
- Spectrum Initiates Phase I Dose Escalation Cancer Study
- CollaGenex Pharmaceuticals Announces Results of Phase 2 Dose-Finding Study of Incyclinide for the Treatment of Rosacea
- Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
- CollaGenex Pharmaceuticals Announces Highly Positive Results of Phase 2 Dose-Finding Trial of Col-118 for the Treatment of Erythema
- CollaGenex Pharmaceuticals Announces Positive Results of Phase 2 Dose-Finding Study of Incyclinide for the Treatment of Acne
- New Phase III Data Show Abbott's HUMIRA(R) (Adalimumab) Was Statistically Superior to Methotrexate in Patients With Psoriasis
- CORRECTING AND REPLACING Study of Claims Data Finds REMICADE Dosing Remains Stable With Maintenance Therapy Over Two Year Period
 |
 |
User Comments (0)
RSS Feeds